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Tirofiban, a specific glycoprotein IIb/IIIa inhibitor, may cause extensive thrombocytopenia with an incidence of 0.2% to 0.5%. We
report the case of a 50-year-oldman who developed thrombocytopenia after tirofiban use (both intracoronary and peripheral) over
hours and the successful management of this complication after primary percutaneous coronary intervention for acute ST-segment
elevation myocardial infarction.
1. Introduction
Glycoprotein IIb/IIIa inhibitors (GPIs) are commonly
employed in treating patients who have unstable angina,
non-ST, and ST-segment elevation myocardial infarction
(STEMI), as well as in combination with angioplasty
with or without stent placement [1]. Tirofiban, a specific and
nonpeptideGPI, competitively inhibits the platelet fibrinogen
receptor and may lead to severe thrombocytopenia with an
incidence of 0.2% to 0.5% [2]. In this report, we describe a
case of acute serious thrombocytopenia after 4 h of tirofiban
administration in a patient in whom primary percutaneous
coronary intervention (PCI) was performed for acute
anterior STEMI.
2. Case Report
A 50-year-old man presented with an acute anterior STEMI.
Initial laboratory tests showed a normal complete blood
count (CBC) including platelet count (265 × 109/L) at the
emergency department. He reports no history of bleeding
disorders, hematologic and renal problems, or heparin expo-
sure. He immediately underwent PCI after pretreatment with
300mg of aspirin and 600mg of clopidogrel and 10.000 IU of
intravenous unfractionated heparin. Coronary angiography
showed the totally occluded left anterior descending artery
(LAD). After predilatation, a large and fresh thrombus was
seen. We first administered tirofiban via intracoronary route
at a dose of 10 𝜇g/kg followed by peripheral intravenous
infusion at 0.15 𝜇g/kg/min and then implanted a coronary 4.5
× 18mm bare metal stent into LAD. A combination therapy
of aspirin, clopidogrel, enoxaparin, and tirofiban infusionwas
given to the patient. Approximately 4 h after the PCI, areas of
petechiae and ecchymoseswere observed around the sternum
and on both legs. The patient’s platelet count was detected to
be 5 × 109/L (Table 1). Checkup on the peripheral smear of
a blood sample validated the extensive lack of platelets with
no clustering. All antiplatelet drugs including tirofiban were
immediately discontinued, and the patient was treated with
Ig G infusion in order to achieve a quick recovery. There
was a very slight rise on day 1, with improvement beginning
after day 2 and counts surpassing 100 × 109/L on day 4
(Table 1). During this time, the patient was supported with
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Table 1: Platelet counts at baseline and after the percutaneous
coronary intervention.











Ig G infusion. Clopidogrel and aspirin were restarted when
the platelet count surpassed 50 × 109/L. In the meantime,
the patient did demonstrate neither any evidence of bleeding
related adverse events nor hemodynamic instability.
3. Discussion
Thrombocytopenia is defined as a platelet count below
the normal range for the population [3]. An accumulating
evidence suggests that there is a clear association between
GPI use and thrombocytopenia [4–8]. Five pictures of
thrombocytopenia caused by GPIs have been described: (i)
acute severe thrombocytopenia within 12 h of first exposure
(platelets <10 × 109/L), (ii) acute thrombocytopenia within
12 h of second exposure, (iii) delayed thrombocytopenia (five
to seven days after treatment), (iv) anaphylaxis after first or
second exposure, and (v) pseudothrombocytopenia [7]. The
main mechanism responsible for GPI-induced thrombocy-
topenia has been proposed to be drug-dependent antibod-
ies that are naturally taking place or induced by previous
exposure to the drug [2, 7, 8]. The differential diagnosis
for some other drug-induced thrombocytopenias should
be punctiliously made. Heparin-induced thrombocytopenia
(HIT) type I tends to occur within minutes to hours of
postexposure in those who have received heparin therapy
within the past 6 months and is usually mild and asymp-
tomatic [9]. InHIT type II, themechanism is immunologic in
origin, and thrombocytopenia typically occurs approximately
5 days after initiation of treatment in patients without prior
exposure to heparin [9]. Although we did not search for
heparin-dependent antibodies, we consider that the acute
severe thrombocytopenia observed in our case was very
unlikely to be heparin induced, because our patient had
no prior exposure to heparin. Aspirin and clopidogrel very
seldom give rise to isolated acute severe thrombocytope-
nia [10]. This patient had no prior history of the use of
these drugs and received aspirin and clopidogrel immedi-
ately before primary PCI and these drugs were resumed 2
days after thrombocytopenia was resolved without further
drop in platelet counts. Clopidogrel may cause thrombotic
thrombocytopenic purpura (TTP), which is characterized
by microangiopathic hemolytic anemia, thrombocytope-
nia, neurologic abnormalities, fever, and renal dysfunction
[10, 11]. In our case, we observed the thrombocytopenia
only, not the other clinical findings of TTP. In addition,
clopidogrel-associated TTP usually develops in the first 2
weeks after initiation of treatment. Tirofiban was given 4 h
prior to the development of thrombocytopenia.The recovery
was completed and sustained after tirofiban was discontin-
ued. Tirofiban was the only drug which was discontinued
and never resumed, whereas aspirin and clopidogrel were
resumed without any problems. The patient sustained a nor-
mal platelet count.Thus, we excluded aspirin and clopidogrel
as a cause for isolated thrombocytopenia. The patient never
had re-exposure to tirofiban later. Therefore, our case had
most probably tirofiban-induced thrombocytopenia. When
thrombocytopenia is diagnosed, it is necessary to interrupt
tirofiban therapy. With termination of tirofiban infusion,
platelet counts usually return to normal levels over a period
of 2 to 5 days (as in our case). During this time, treatment
with steroids, Ig infusion, and platelet transfusion may be life
saving [2–7]. In pseudothrombocytopenia, there is neither
in vivo thrombocytopenia nor increased aggregation. This
artifactual clumping of platelets should be ruled out by
manually testing peripheral blood smears or repeating the
platelet count in blood samples anticoagulated with citrate
[2, 3]. To our knowledge, there is no report in which tirofiban
was found to be related to pseudothrombocytopenia.
In conclusion, our report illustrates the importance of
awareness of the life threatening thrombocytopenia associ-
ated with intracoronary tirofiban use. The measurement of
platelet count before and early after the initiation of tirofiban
treatment is very important because the tirofiban-induced
thrombocytopenia can be resolved by the interruption of
tirofiban infusion and early supportive treatment.
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